Revolutionary RSV Drug Beyfortus Launches in India

In a significant move to combat respiratory syncytial virus (RSV) in infants, Dr Reddy’s Laboratories has announced an expanded partnership with Sanofi Healthcare India Pvt Ltd (SHIPL) to introduce Beyfortus, a novel monoclonal antibody drug, to the Indian market.

Global Approval and Indian Authorization

Having received approvals in the European Union, US, China, and Japan, Beyfortus was granted marketing authorization by India’s Central Drugs Standard Control Organisation (CDSCO) in June last year. This marks a pivotal step in addressing RSV, a leading cause of lower respiratory tract disease in infants.

Exclusive Distribution Rights

Dr Reddy’s will hold exclusive rights to promote and distribute Beyfortus in India, following a similar partnership for Sanofi’s vaccine portfolio. The drug is set to be available in prefilled injections by the second quarter of the current fiscal year.

Addressing a Critical Health Challenge

RSV affects two out of three infants in their first year and nearly all by their second birthday, leading to significant hospitalizations worldwide. Beyfortus offers a much-needed solution to protect vulnerable infants from severe RSV disease.

Leadership Perspectives

Nitya Padmanabhan of Sanofi Vaccines emphasized the importance of early protection in India's high disease burden context. MV Ramana from Dr Reddy’s highlighted how Beyfortus strengthens their immunization portfolio, promising a healthier future for India’s children.